Would you like to know if you are eligible for the Neridronate Treatment? Book your free video call now!

CRPS Treatment: pain in left leg for 4.5 years

General details and patient's info

Age:32 years old at the time of treatment.
Home Country:Australia.
Illness duration:4.5 years prior to the Neridronate Treatment.
Cause:Knee replacement surgery.
Symptoms:The symptoms are present from the knee down in the left leg, patient feels burning pain daily; leg’s skin is shiny and turns purple as soon as she walks; hair growth is abnormal on the lower part of the leg.
Clinical evaluation:CRPS. 
Time of treatment:June 2021.

Why the Patient decided to undergo the CRPS Treatment in Italy

She had found us via YouTube, watching our Patient’s Testimonials. When she saw a video about a patient with a similar case and the improvements he had seen after treatment, she decided to contact us.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
3 sessions Neuromuscular Rehabilitation Treatment Treatment with Physiotherapist.
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.
7 days Light Therapy (in hotel room, 30+ more minutes each day)
30 minutes or more of usage of the MTI Light Therapy reduces inflammation, increase micro-circulation, relax nerves and muscles, reduces pain transmission, accelerates healing, regenerates cells, and promotes cells activation.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by her Patient Manager, followed by check-in at her Hotel in Verona. Briefing focused on the next days.

DAY 2: Rest day in the hotel, in contact with her Patient Manager.
DAY 3: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor, 1st Rehabilitation session, and 1st infusions.

DAY 4: Morning pick-up by her Patient Manager, 2nd infusions.

DAY 5: Rest day in the hotel, in contact with her Patient Manager.

DAY 6: Morning pick-up by her Patient Manager, 2nd Rehabilitation session and 3rd infusions.

DAY 7: Morning pick-up by her Patient Manager, 3rd Rehabilitation session, 4th infusions and 2nd visit with the Rheumatologist Professor. Tourism in Verona.

DAY 8: Pick-up by her Patient Manager, check-out, and drop-off at the Venice airport for her trip back home.

Follow up

AUGUST 2021 (2 months after Neridronate treatment): the patient says she can already feel her whole leg “changing”. The pain levels have dropped from a daily 8 to a daily 5.

DECEMBER 2023 (6 months after Neridronate treatment): The patient refers to her leg not changing color anymore. The pain levels have now dropped to a daily 2 which she is incredibly happy about. She can now walk normally without having issues while doing so.


This patient arrived in Italy with a pain level at 8, and 6 months later it had dropped at 2. For this woman, who had fought CRPS for 4.5 years, it was a life-changing experience. Years later, she still confirms het improvements are lasting and even sponsored another patient into coming to Italy.

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.